Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Assessment of sphingosine-1-phosphate receptor expression and associated intracellular signaling cascades in primary cells of the human central nervous system.
Glatiramer acetate does not protect from acute ischemic stroke in mice.
US top court denies Israel's Teva Pharmaceuticals stay in Copaxone patent fight
Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
Axonal conduction and injury in multiple sclerosis: the role of sodium channels.
Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)
Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.
Neuropathology of white matter disease in Leber's hereditary optic neuropathy.
Food and Drug Administration Approval Letter for Alemtuzumab
Sex-related factors in multiple sclerosis susceptibility and progression.
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
Biomarkers for Brain Disorders: Challenges and Opportunities
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota.
Demyelination affects temporal aspects of perception: An optic neuritis study.
Remyelination therapy goes to trial for multiple sclerosis
Mycoplasma pneumonia seroposivity in Iranian patients with relapsing-remitting multipl sclerosis: a randomized case-control study.
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
Poor sleep in patients with multiple sclerosis.
Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.

Pages